Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Akt-dependent mechanism

Biochemical and Biophysical Research Communications

Volumn 435, Issue 1, 2013, Pages 107-112

  Yang, Ya Luen ^a   Huang, Po Hsien ^a   Chiu, Hao Chieh ^b   Kulp, Samuel K ^c   Chen, Ching Shih ^c   Kuo, Cheng Ju ^a   Chen, Huan Da ^a   Chen, Chang Shi ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Glioma; Histone deacetylase inhibitor; PI3K Akt pathway; Telomerase reverse transcriptase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AR 42; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TELOMERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GLIOMA CELL; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

CELL LINE, TUMOR; CHROMONES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HISTONE DEACETYLASE INHIBITORS; HUMANS; MORPHOLINES; MUTATION; PHENYLBUTYRATES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TELOMERASE;

EID: 84878188953     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.04.049     Document Type: Article

References (34)

1. Blackburn E.H. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett. 2005, 579:859-862.
2. Watson J.D. Origin of concatemeric T7 DNA. Nat. New Biol. 1972, 239:197-201.
3. Artandi S.E., DePinho R.A. A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr. Opin. Genet. Dev. 2000, 10:39-46.
4. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer 1997, 33:787-791.
5. Nugent C.I., Lundblad V. The telomerase reverse transcriptase: components and regulation. Genes Dev. 1998, 12:1073-1085.
6. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
7. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., Wright W.E. Extension of life-span by introduction of telomerase into normal human cells. Science 1998, 279:349-352.
8. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 1999, 400:464-468.
9. Cong Y.S., Bacchetti S. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J. Biol. Chem. 2000, 275:35665-35668.
10. Hou M., Wang X., Popov N., Zhang A., Zhao X., Zhou R., Zetterberg A., Bjorkholm M., Henriksson M., Gruber A., Xu D. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp. Cell Res. 2002, 274:25-34.
11. Nakamura M., Saito H., Ebinuma H., Wakabayashi K., Saito Y., Takagi T., Nakamoto N., Ishii H. Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor. J. Cell. Physiol. 2001, 187:392-401.
12. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28:1075-1083.
13. Liu J.P. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. 1999, 13:2091-2104.
14. Chen C.S., Weng S.C., Tseng P.H., Lin H.P. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 2005, 280:38879-38887.
15. Kulp S.K., Chen C.S., Wang D.S., Chen C.Y., Chen C.S. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin. Cancer Res. 2006, 12:5199-5206.
16. Lu Y.S., Kashida Y., Kulp S.K., Wang Y.C., Wang D., Hung J.H., Tang M., Lin Z.Z., Chen T.J., Cheng A.L., Chen C.S. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 2007, 46:1119-1130.
17. Jacob A., Oblinger J., Bush M.L., Brendel V., Santarelli G., Chaudhury A.R., Kulp S., La Perle K.M., Chen C.S., Chang L.S., Welling D.B. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. Laryngoscope 2012, 122:174-189.
18. Lu Q., Wang D.S., Chen C.S., Hu Y.D., Chen C.S. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J. Med. Chem. 2005, 48:5530-5535.
19. Kulp S.K., Yang Y.T., Hung C.C., Chen K.F., Lai J.P., Tseng P.H., Fowble J.W., Ward P.J., Chen C.S. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 2004, 64:1444-1451.
20. Suenaga M., Soda H., Oka M., Yamaguchi A., Nakatomi K., Shiozawa K., Kawabata S., Kasai T., Yamada Y., Kamihira S., Tei C., Kohno S. Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. Int. J. Cancer 2002, 97:621-625.
21. Chen C.S., Wang Y.C., Yang H.C., Huang P.H., Kulp S.K., Yang C.C., Lu Y.S., Matsuyama S., Chen C.Y., Chen C.S. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res. 2007, 67:5318-5327.
22. Liu Y.L., Yang P.M., Shun C.T., Wu M.S., Weng J.R., Chen C.C. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy 2010, 6:1057-1065.
23. Woo H.J., Lee S.J., Choi B.T., Park Y.M., Choi Y.H. Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor in human leukemic U937 cells. Exp. Mol. Pathol. 2007, 82:77-84.
24. Takakura M., Kyo S., Kanaya T., Hirano H., Takeda J., Yutsudo M., Inoue M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 1999, 59:551-557.
25. Mukhopadhyay N.K., Gordon G.J., Maulik G., Doerre G., Liu B.C., Bueno R., Sugarbaker D.J., Jaklitsch M.T. Histone deacetylation is directly involved in desilencing the expression of the catalytic subunit of telomerase in normal lung fibroblast. J. Cell. Mol. Med. 2005, 9:662-669.
26. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
27. Lin H.Y., Chen C.S., Lin S.P., Weng J.R., Chen C.S. Targeting histone deacetylase in cancer therapy. Med. Res. Rev. 2006, 26:397-413.
28. Huang P.H., Chen C.H., Chou C.C., Sargeant A.M., Kulp S.K., Teng C.M., Byrd J.C., Chen C.S. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Mol. Pharmacol. 2011, 79:197-206.
29. Nimmanapalli R., Fuino L., Stobaugh C., Richon V., Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003, 101:3236-3239.
30. Kodani M., Igishi T., Matsumoto S., Chikumi H., Shigeoka Y., Nakanishi H., Morita M., Yasuda K., Hitsuda Y., Shimizu E. Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells. Oncol. Rep. 2005, 13:477-483.
31. Wojtyla A., Gladych M., Rubis B. Human telomerase activity regulation. Mol. Biol. Rep. 2011, 38:3339-3349.
32. Chung J., Khadka P., Chung I.K. Nuclear import of hTERT requires a bipartite nuclear localization signal and Akt-mediated phosphorylation. J. Cell Sci 2012, 125:2684-2697.
33. Chai H., Zhang Y., Tan W.H., Chng W.J., Li B., Wang X. Regulation of hTERT by BCR-ABL at multiple levels in K562 cells. BMC Cancer 2011, 11:512.
34. Chang T., Lu Y.C., Chen Y.J., Tseng C.P., Chen Y.L., Fang C.W., Cheng A.J. hTERT phosphorylation by PKC is essential for telomerase holoprotein integrity and enzyme activity in head neck cancer cells. Br. J. Cancer 2006, 94:870-878.